Polar Capital Global Healthcare Trust plc (PCGH) - Cash Flow Conversion Efficiency

Latest as of March 2026: -0.003x

Based on the latest financial reports, Polar Capital Global Healthcare Trust plc (PCGH) has a cash flow conversion efficiency ratio of -0.003x as of March 2026. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (GBX-1.22 Million ≈ $-147.95 USD) by net assets (GBX377.05 Million ≈ $45.88K USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. See PCGH defensive interval ratio to measure how many days the company can operate on defensive assets alone.

Polar Capital Global Healthcare Trust plc - Cash Flow Conversion Efficiency Trend (2012–2025)

This chart illustrates how Polar Capital Global Healthcare Trust plc's cash flow conversion efficiency has evolved over time, based on yearly financial data.

Polar Capital Global Healthcare Trust plc Competitors by Cash Flow Conversion Efficiency

The table below lists competitors of Polar Capital Global Healthcare Trust plc ranked by their cash flow conversion efficiency.

Company Cash Flow Conversion Efficiency
Gelteq Limited Ordinary Shares
NASDAQ:GELS
-0.019x
333D Ltd
AU:T3D
0.084x
Aston Martin Lagonda Global Holdings PLC
LSE:AML
0.252x
Throgmorton Trust Plc
LSE:THRG
0.018x
Albion Resources Ltd
AU:ALB
-0.617x
Golden Metal Resources PLC
LSE:GMET
-0.027x
Me Group International PLC
LSE:MEGP
0.180x
CaliberCos Inc. Class A Common Stock
NASDAQ:CWD
-0.173x

Annual Cash Flow Conversion Efficiency for Polar Capital Global Healthcare Trust plc (2012–2025)

The table below shows the annual cash flow conversion efficiency of Polar Capital Global Healthcare Trust plc from 2012 to 2025. For the full company profile with market capitalisation and key ratios, see Polar Capital Global Healthcare Trust pl (PCGH) market capitalisation.

Year Net Assets Operating Cash Flow Cash Flow Conversion Efficiency Change
2025-09-30 GBX448.11 Million
≈ $54.52K
GBX-1.43 Million
≈ $-173.87
-0.003x -5192.46%
2024-09-30 GBX479.07 Million
≈ $58.29K
GBX30.00K
≈ $3.65
0.000x +101.15%
2023-09-30 GBX419.18 Million
≈ $51.00K
GBX-2.29 Million
≈ $-278.51
-0.005x +40.95%
2022-12-31 GBX404.83 Million
≈ $49.26K
GBX-3.74 Million
≈ $-455.54
-0.009x 0.00%
2022-09-30 GBX404.83 Million
≈ $49.26K
GBX-3.74 Million
≈ $-455.54
-0.009x -129.82%
2021-12-31 GBX422.19 Million
≈ $51.37K
GBX-1.70 Million
≈ $-206.72
-0.004x +8.64%
2021-09-30 GBX385.73 Million
≈ $46.93K
GBX-1.70 Million
≈ $-206.72
-0.004x -110.89%
2020-12-31 GBX360.54 Million
≈ $43.87K
GBX14.58 Million
≈ $1.77K
0.040x -9.82%
2020-09-30 GBX325.13 Million
≈ $39.56K
GBX14.58 Million
≈ $1.77K
0.045x +1110.61%
2019-09-30 GBX288.45 Million
≈ $35.10K
GBX-1.28 Million
≈ $-155.74
-0.004x -109.19%
2018-09-30 GBX296.26 Million
≈ $36.05K
GBX14.30 Million
≈ $1.74K
0.048x +130.98%
2017-09-30 GBX250.13 Million
≈ $30.43K
GBX-38.99 Million
≈ $-4.74K
-0.156x -452.71%
2016-09-30 GBX247.82 Million
≈ $30.15K
GBX10.95 Million
≈ $1.33K
0.044x +22.77%
2015-09-30 GBX210.44 Million
≈ $25.60K
GBX7.58 Million
≈ $921.66
0.036x +154.94%
2014-09-30 GBX199.96 Million
≈ $24.33K
GBX-13.10 Million
≈ $-1.59K
-0.066x -81.49%
2013-09-30 GBX155.75 Million
≈ $18.95K
GBX-5.62 Million
≈ $-684.16
-0.036x -19.85%
2012-09-30 GBX120.74 Million
≈ $14.69K
GBX-3.64 Million
≈ $-442.52
-0.030x --

About Polar Capital Global Healthcare Trust plc

LSE:PCGH UK Asset Management
Market Cap
$5.03 Million
GBX41.37 Billion GBX
Market Cap Rank
#28560 Global
#475 in UK
Share Price
GBX412.50
Change (1 day)
-1.32%
52-Week Range
GBX322.00 - GBX437.00
All Time High
GBX437.00
About

Polar Capital Global Healthcare Trust plc is a closed ended equity mutual fund launched and managed by Polar Capital LLP. The fund invests in public equity markets across the globe. It seeks to invest in stocks of companies operating in the healthcare sector, with an emphasis on companies involved in pharmaceuticals, medical services, medical devices, and biotechnology. The fund primarily invests… Read more